SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337342.
  • 2
    Suda T, Nakamura I, Jimi E, Takahashi N 1997 Regulation of osteoclast function. J Bone Miner Res 12:869879.
  • 3
    Karsenty G 1999 The genetic transformation of bone biology. Genes Dev 13:30373051.
  • 4
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165176.
  • 5
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:35973602.
  • 6
    Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD 1990 The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442444.
  • 7
    Dai X, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER 2002 Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99:111120.
  • 8
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315323.
  • 9
    Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J 1999 RANK is essential for osteoclast and lymph node development. Genes Dev 13:24122424.
  • 10
    Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T 2003 The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4:281289.
  • 11
    Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M 1995 Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 144:195223.
  • 12
    Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S 1999 Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255259.
  • 13
    Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R 2000 Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106:12291237.
  • 14
    Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y 2000 Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: Implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15:13211329.
  • 15
    Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P 2001 Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:2065920672.
  • 16
    Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R 1996 Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem 271:2889028897.
  • 17
    Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL 2000 Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275:2730727310.
  • 18
    Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ 2002 TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143:11081118.
  • 19
    Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275286.
  • 20
    Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A 2000 Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275:48584864.
  • 21
    Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL 2000 TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:14811488.
  • 22
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304309.
  • 23
    Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM 2001 TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:16891699.
  • 24
    Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT 2002 Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:14191427.
  • 25
    Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G 2002 Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46:785792.
  • 26
    Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM 2003 Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821831.
  • 27
    Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney JR, Ritchlin CT, Boyce BF, Xing L 2003 Systemic TNFa mediates an increase in periphery CD11bhi osteoclast progenitors in TNFα transgenic mice. Arthritis Rheum (in press)
  • 28
    Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L, Kollias G 1995 Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm 47:2738.
  • 29
    Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR 1992 Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90:16221627.
  • 30
    Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:34823496.
  • 31
    Li P, Sanz I, O'Keefe RJ, Schwarz EM 2000 NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol 164:59905997.
  • 32
    Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM 1997 DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition. J Immunol 159:28672876.
  • 33
    Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:15661571.
  • 34
    Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM 2002 In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17:192199.
  • 35
    Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, Dougall WC, Anderson D, O'Keefe RJ, Schwarz EM 2003 Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res 21:676684.
  • 36
    Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:17411754.
  • 37
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175179.
  • 38
    Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y 2001 Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276:563568.
  • 39
    Bromley M, Woolley DE 1984 Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum 27:857863.
  • 40
    Bromley M, Woolley DE 1984 Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968975.
  • 41
    Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR 2000 Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250258.
  • 42
    Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S 2000 Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259269.